Leveraging RWE and Advanced Analytics: The Need for a Modernized Drug Development Model in a Pandemic

This interactive discussion featured Harry Glorikian, Chair of AI in Biopharma Summit and author of MoneyBall Medicine joined by Ülo Palm, Thomas Bock, and Lixia Wang, who were open to discussion and debate about topics including:

• The definition of RWE
• Examples of companies that are effectively working with biopharma to ensure that RWD is thoughtfully collected and analyzed to turn it into a powerful tool
• The ability of RWE to predict future pandemics
• Challenges to adoption
• Privacy concerns
• The potential over-reliance on p-values
• RCT’s (random clinical trials) limitations on drug efficacy in big populations
• Working with regulators

See link: https://bit.ly/2TpeRqo